Special Drug Use-results Surveillance of Scemblix Tablets
1 other identifier
observational
550
1 country
278
Brief Summary
Uncontrolled, central registration system, all-case, multicenter, special drug use-results surveillance.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2022
278 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 13, 2022
CompletedFirst Posted
Study publicly available on registry
June 16, 2022
CompletedStudy Start
First participant enrolled
July 4, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 29, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
February 29, 2024
CompletedMarch 27, 2024
March 1, 2024
1.7 years
June 13, 2022
March 26, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Type, frequency, seriousness and severity of adverse event (AE)/treatment-related AE of the safety specifications
For the safety specifications (myelosuppression, infections, QT interval prolongation, pancreatitis, vascular occlusive events, photosensitivity), type, frequency AE, seriousness, severity of adverse event (AE)/treatment-related AE will be collected
Up to 48 Weeks
AEs leading to interruption/discontinuation of the safety specifications
For the safety specifications (myelosuppression, infections, QT interval prolongation, pancreatitis, vascular occlusive events, photosensitivity), AEs leading to interruption/discontinuation will be collected
Up to 48 Weeks
Number of patients with changes in relevant laboratory parameters for the safety specifications
For the safety specifications (myelosuppression, infections, QT interval prolongation, pancreatitis, vascular occlusive events, photosensitivity), number of patients with changes in relevant laboratory parameters will be collected
Up to 48 Weeks
Frequency of AEs/Treatment-related AEs by patient characteristic factor
Frequency of AEs/Treatment-related AEs by patient characteristic factor will be collected
Up to 48 Weeks
Secondary Outcomes (19)
Type, frequency, seriousness, severity of AEs/treatment-related AEs of the safety analysis set
Up to 48 Weeks
AEs leading to interruption/discontinuation in the safety analysis set
Up to 48 Weeks
Frequency of AEs/treatment-related AEs summarized by patient characteristic factor
Up to 48 Weeks
Type, frequency, seriousness, severity of AEs/treatment-related AEs in patients with special characteristics
Up to 48 Weeks
AEs leading to interruption/discontinuation in patients with special characteristics
Up to 48 Weeks
- +14 more secondary outcomes
Study Arms (1)
Asciminib
Patients prescribed with Asciminib
Interventions
Prospective observational study. There is no treatment allocation. Patients prescribed with asciminib are eligible to enroll into this study.
Eligibility Criteria
Patients treated with asciminib
You may qualify if:
- patients treated with asciminib in Japan.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (278)
Novartis Investigative Site
Anjo, Aichi-ken, 446-8602, Japan
Novartis Investigative Site
Ichinomiya, Aichi-ken, 491-0041, Japan
Novartis Investigative Site
Kasugai, Aichi-ken, 486-8510, Japan
Novartis Investigative Site
Komaki, Aichi-ken, 485-8520, Japan
Novartis Investigative Site
Kōnan, Aichi-ken, 483-8704, Japan
Novartis Investigative Site
Nagakute, Aichi-ken, 480-1195, Japan
Novartis Investigative Site
Nagoya, Aichi-ken, 453-8511, Japan
Novartis Investigative Site
Nagoya, Aichi-ken, 457 8510, Japan
Novartis Investigative Site
Nagoya, Aichi-ken, 460-0001, Japan
Novartis Investigative Site
Nagoya, Aichi-ken, 466-8650, Japan
Novartis Investigative Site
Nagoya, Aichi-ken, 467-8602, Japan
Novartis Investigative Site
Seto, Aichi-ken, 489-8642, Japan
Novartis Investigative Site
Toyoake, Aichi-ken, 470 1192, Japan
Novartis Investigative Site
Toyohashi, Aichi-ken, 441-8111, Japan
Novartis Investigative Site
Toyohashi, Aichi-ken, 441-8570, Japan
Novartis Investigative Site
Tōkai, Aichi-ken, 477-8522, Japan
Novartis Investigative Site
Yatomi, Aichi-ken, 498-8502, Japan
Novartis Investigative Site
Ōdate, Akita, 017-8550, Japan
Novartis Investigative Site
Funabashi, Chiba, 273-8556, Japan
Novartis Investigative Site
Ichihara, Chiba, 290-0003, Japan
Novartis Investigative Site
Ichikawa, Chiba, 272-8513, Japan
Novartis Investigative Site
Kashiwa, Chiba, 277 8577, Japan
Novartis Investigative Site
Kashiwa, Chiba, 277-8567, Japan
Novartis Investigative Site
Kisarazu, Chiba, 292-8535, Japan
Novartis Investigative Site
Matsudo, Chiba, 270-0034, Japan
Novartis Investigative Site
Narita, Chiba, 286-8523, Japan
Novartis Investigative Site
Matsuyama, Ehime, 790-0024, Japan
Novartis Investigative Site
Matsuyama, Ehime, 790-0067, Japan
Novartis Investigative Site
Matsuyama, Ehime, 790-8524, Japan
Novartis Investigative Site
Tōon, Ehime, 791-0295, Japan
Novartis Investigative Site
Yoshida-gun, Fukui, 910-1193, Japan
Novartis Investigative Site
Fukuoka, Fukuoka, 812-8582, Japan
Novartis Investigative Site
Kitakyushu, Fukuoka, 802-8555, Japan
Novartis Investigative Site
Kitakyushu, Fukuoka, 806-8501, Japan
Novartis Investigative Site
Kitakyushu, Fukuoka, 807-8556, Japan
Novartis Investigative Site
Kurume, Fukuoka, 830-8543, Japan
Novartis Investigative Site
Yanagawa, Fukuoka, 832-0059, Japan
Novartis Investigative Site
Aizu-Wakamatsu, Fukushima, 969-3482, Japan
Novartis Investigative Site
Fukushima, Fukushima, 960 1295, Japan
Novartis Investigative Site
Iwaki, Fukushima, 973-8402, Japan
Novartis Investigative Site
Gifu, Gifu, 501-1194, Japan
Novartis Investigative Site
Sekimachi, Gifu, 501-3802, Japan
Novartis Investigative Site
Takayama, Gifu, 506-8550, Japan
Novartis Investigative Site
Fujioka, Gunma, 375-8503, Japan
Novartis Investigative Site
Maebashi, Gunma, 371 8511, Japan
Novartis Investigative Site
Maebashi, Gunma, 371-0811, Japan
Novartis Investigative Site
Maebashi, Gunma, 371-0821, Japan
Novartis Investigative Site
Ōta, Gunma, 373-8550, Japan
Novartis Investigative Site
Fukuyama, Hiroshima, 720-0001, Japan
Novartis Investigative Site
Mihara, Hiroshima, 723-0014, Japan
Novartis Investigative Site
Asahikawa, Hokkaido, 078-8211, Japan
Novartis Investigative Site
Hakodate, Hokkaido, 041-0821, Japan
Novartis Investigative Site
Iwamizawa, Hokkaido, 068-8555, Japan
Novartis Investigative Site
Kushiro, Hokkaido, 085-0052, Japan
Novartis Investigative Site
Obihiro, Hokkaido, 080-0024, Japan
Novartis Investigative Site
Sapporo, Hokkaido, 003-0006, Japan
Novartis Investigative Site
Sapporo, Hokkaido, 004-8618, Japan
Novartis Investigative Site
Sapporo, Hokkaido, 007-0805, Japan
Novartis Investigative Site
Sapporo, Hokkaido, 060-0004, Japan
Novartis Investigative Site
Sapporo, Hokkaido, 060-8543, Japan
Novartis Investigative Site
Akashi, Hyōgo, 673-8558, Japan
Novartis Investigative Site
Amagasaki, Hyōgo, 660 8550, Japan
Novartis Investigative Site
Amagasaki, Hyōgo, 660-8511, Japan
Novartis Investigative Site
Himeji, Hyōgo, 670-8540, Japan
Novartis Investigative Site
Kakogawa-shi, Hyōgo, 675-8611, Japan
Novartis Investigative Site
Kobe, Hyōgo, 650-0017, Japan
Novartis Investigative Site
Kobe, Hyōgo, 650-0047, Japan
Novartis Investigative Site
Kobe, Hyōgo, 651-0072, Japan
Novartis Investigative Site
Kobe, Hyōgo, 651-1145, Japan
Novartis Investigative Site
Kobe, Hyōgo, 651-2273, Japan
Novartis Investigative Site
Kobe, Hyōgo, 657-0064, Japan
Novartis Investigative Site
Nishinomiya, Hyōgo, 662-0918, Japan
Novartis Investigative Site
Nishinomiya, Hyōgo, 663 8501, Japan
Novartis Investigative Site
Nishinomiya, Hyōgo, 663-8186, Japan
Novartis Investigative Site
Sumoto, Hyōgo, 656-0021, Japan
Novartis Investigative Site
Toyooka, Hyōgo, 668-8501, Japan
Novartis Investigative Site
Higashiibaraki-gun, Ibaraki, 311-3193, Japan
Novartis Investigative Site
Hitachi, Ibaraki, 317-0077, Japan
Novartis Investigative Site
Ishioka, Ibaraki, 315-0037, Japan
Novartis Investigative Site
Koga, Ibaraki, 306-0232, Japan
Novartis Investigative Site
Tsuchiura, Ibaraki, 300-0028, Japan
Novartis Investigative Site
Tsukuba, Ibaraki, 300-2622, Japan
Novartis Investigative Site
Tsukuba, Ibaraki, 305-8576, Japan
Novartis Investigative Site
Kanazawa, Ishikawa-ken, 920-0853, Japan
Novartis Investigative Site
Kanazawa, Ishikawa-ken, 920-8641, Japan
Novartis Investigative Site
Nanao, Ishikawa-ken, 926-0866, Japan
Novartis Investigative Site
Nomi, Ishikawa-ken, 923-1226, Japan
Novartis Investigative Site
Kitakami, Iwate, 024-0004, Japan
Novartis Investigative Site
Morioka, Iwate, 020 0066, Japan
Novartis Investigative Site
Shiwa-gun, Iwate, 028-3695, Japan
Novartis Investigative Site
Kita-gun, Kagawa-ken, 761-0793, Japan
Novartis Investigative Site
Takamatsu, Kagawa-ken, 760 8557, Japan
Novartis Investigative Site
Takamatsu, Kagawa-ken, 760-0017, Japan
Novartis Investigative Site
Takamatsu, Kagawa-ken, 761-8538, Japan
Novartis Investigative Site
Kanoya, Kagoshima-ken, 893-0024, Japan
Novartis Investigative Site
Kirishima, Kagoshima-ken, 899-5112, Japan
Novartis Investigative Site
Kamakura, Kanagawa, 247-8533, Japan
Novartis Investigative Site
Kawasaki, Kanagawa, 211-8510, Japan
Novartis Investigative Site
Kawasaki, Kanagawa, 216-8511, Japan
Novartis Investigative Site
Kawasaki, Kanagawa, 255, Japan
Novartis Investigative Site
Yamato, Kanagawa, 242-8602, Japan
Novartis Investigative Site
Yokohama, Kanagawa, 221-0855, Japan
Novartis Investigative Site
Yokohama, Kanagawa, 227-8501, Japan
Novartis Investigative Site
Yokohama, Kanagawa, 232 0024, Japan
Novartis Investigative Site
Yokohama, Kanagawa, 236-0004, Japan
Novartis Investigative Site
Yokohama, Kanagawa, 241-0811, Japan
Novartis Investigative Site
Kochi, Kochi, 781 8555, Japan
Novartis Investigative Site
Kumamoto, Kumamoto, 860-8556, Japan
Novartis Investigative Site
Kumamoto, Kumamoto, 861-4193, Japan
Novartis Investigative Site
Kumamoto, Kumamoto, 861-8520, Japan
Novartis Investigative Site
Kumamoto, Kumamoto, 862-8655, Japan
Novartis Investigative Site
Fukuchiyama, Kyoto, 620-8505, Japan
Novartis Investigative Site
Kyoto, Kyoto, 604-8845, Japan
Novartis Investigative Site
Maizuru, Kyoto, 625-0036, Japan
Novartis Investigative Site
Tsu, Mie-ken, 514-0057, Japan
Novartis Investigative Site
Tsu, Mie-ken, 514-8507, Japan
Novartis Investigative Site
Yokkaichi, Mie-ken, 510-8567, Japan
Novartis Investigative Site
Ishinomaki, Miyagi, 986-0861, Japan
Novartis Investigative Site
Sendai, Miyagi, 980 8574, Japan
Novartis Investigative Site
Sendai, Miyagi, 982-0007, Japan
Novartis Investigative Site
Sendai, Miyagi, 983 8512, Japan
Novartis Investigative Site
Sendai, Miyagi, 983 8520, Japan
Novartis Investigative Site
Miyakonojō, Miyazaki, 885-0014, Japan
Novartis Investigative Site
Miyakonojō, Miyazaki, 885-0035, Japan
Novartis Investigative Site
Nobeoka, Miyazaki, 882-0835, Japan
Novartis Investigative Site
Nagano, Nagano, 380-8582, Japan
Novartis Investigative Site
Saku, Nagano, 3850051, Japan
Novartis Investigative Site
Suwa, Nagano, 392-8510, Japan
Novartis Investigative Site
Isahaya, Nagasaki, 854-0071, Japan
Novartis Investigative Site
Nagasaki, Nagasaki, 852-8511, Japan
Novartis Investigative Site
Ikoma, Nara, 630-0293, Japan
Novartis Investigative Site
Kashihara, Nara, 634 8522, Japan
Novartis Investigative Site
Tenri, Nara, 632-8552, Japan
Novartis Investigative Site
Jōetsu, Niigata, 943-0147, Japan
Novartis Investigative Site
Minamiuonuma, Niigata, 949-7302, Japan
Novartis Investigative Site
Nagaoka, Niigata, 940-2085, Japan
Novartis Investigative Site
Shibata, Niigata, 957-8588, Japan
Novartis Investigative Site
Yufu, Oita Prefecture, 879-5593, Japan
Novartis Investigative Site
Kurashiki, Okayama-ken, 710-8602, Japan
Novartis Investigative Site
Okayama, Okayama-ken, 700-8558, Japan
Novartis Investigative Site
Okayama, Okayama-ken, 700-8607, Japan
Novartis Investigative Site
Okayama, Okayama-ken, 701-1192, Japan
Novartis Investigative Site
Tsuyama, Okayama-ken, 708-0841, Japan
Novartis Investigative Site
Nago, Okinawa, 905-0011, Japan
Novartis Investigative Site
Naha, Okinawa, 902-8511, Japan
Novartis Investigative Site
Shimajiri-Gun, Okinawa, 901-1303, Japan
Novartis Investigative Site
Hirakata, Osaka, 573-1191, Japan
Novartis Investigative Site
Izumisano, Osaka, 598-8577, Japan
Novartis Investigative Site
Kawachi-Nagano, Osaka, 586-0008, Japan
Novartis Investigative Site
Kawachi-Nagano, Osaka, 586-8521, Japan
Novartis Investigative Site
Moriguchi, Osaka, 570-8507, Japan
Novartis Investigative Site
Moriguchi, Osaka, 570-8540, Japan
Novartis Investigative Site
Osaka, Osaka, 530-0012, Japan
Novartis Investigative Site
Osaka, Osaka, 541-8567, Japan
Novartis Investigative Site
Osaka, Osaka, 543-8555, Japan
Novartis Investigative Site
Osaka, Osaka, 550-0006, Japan
Novartis Investigative Site
Ōsaka-sayama, Osaka, 589 8511, Japan
Novartis Investigative Site
Suita, Osaka, 564-0082, Japan
Novartis Investigative Site
Suita, Osaka, 565 0871, Japan
Novartis Investigative Site
Takatsuki, Osaka, 569-1096, Japan
Novartis Investigative Site
Tondabayashi, Osaka, 584-0091, Japan
Novartis Investigative Site
Toyonaka, Osaka, 560-8565, Japan
Novartis Investigative Site
Karatsu, Saga-ken, 847-0000, Japan
Novartis Investigative Site
Saga, Saga-ken, 849-8501, Japan
Novartis Investigative Site
Asaka, Saitama, 351-0021, Japan
Novartis Investigative Site
Fukaya, Saitama, 366-0052, Japan
Novartis Investigative Site
Hidaka, Saitama, 350-1298, Japan
Novartis Investigative Site
Iruma-gun, Saitama, 350-0495, Japan
Novartis Investigative Site
Kawagoe, Saitama, 350 8550, Japan
Novartis Investigative Site
Koshigaya, Saitama, 343-8555, Japan
Novartis Investigative Site
Sayama, Saitama, 350-1305, Japan
Novartis Investigative Site
Tokorozawa, Saitama, 359 8513, Japan
Novartis Investigative Site
Tokorozawa, Saitama, 359-0037, Japan
Novartis Investigative Site
Kusatsu, Shiga, 525 8585, Japan
Novartis Investigative Site
Moriyama, Shiga, 524-8524, Japan
Novartis Investigative Site
Nagahama, Shiga, 526-0831, Japan
Novartis Investigative Site
Ōmihachiman, Shiga, 523-0082, Japan
Novartis Investigative Site
Izumo, Shimane, 693 8501, Japan
Novartis Investigative Site
Izumo, Shimane, 693-0068, Japan
Novartis Investigative Site
Masuda, Shimane, 698-0003, Japan
Novartis Investigative Site
Matsue, Shimane, 690-8506, Japan
Novartis Investigative Site
Hamamatsu, Shizuoka, 430-8558, Japan
Novartis Investigative Site
Hamamatsu, Shizuoka, 431-3192, Japan
Novartis Investigative Site
Iwata, Shizuoka, 438-8550, Japan
Novartis Investigative Site
Izunokuni, Shizuoka, 410-2295, Japan
Novartis Investigative Site
Shimada, Shizuoka, 427-8502, Japan
Novartis Investigative Site
Shizuoka, Shizuoka, 420-8630, Japan
Novartis Investigative Site
Sunto Gun, Shizuoka, 411 8777, Japan
Novartis Investigative Site
Sano, Tochigi, 327-8511, Japan
Novartis Investigative Site
Shimotsuke, Tochigi, 329-0498, Japan
Novartis Investigative Site
Komatsushimachō, Tokushima, 773-8502, Japan
Novartis Investigative Site
Okuno, Tokushima, 771-0204, Japan
Novartis Investigative Site
Bunkyo Ku, Tokyo, 113-8431, Japan
Novartis Investigative Site
Bunkyo Ku, Tokyo, 113-8677, Japan
Novartis Investigative Site
Bunkyo-ku, Tokyo, 113-8603, Japan
Novartis Investigative Site
Chiyoda-ku, Tokyo, 101-8643, Japan
Novartis Investigative Site
Chiyoda-ku, Tokyo, 102-8798, Japan
Novartis Investigative Site
Hachiōji, Tokyo, 192-0032, Japan
Novartis Investigative Site
Hachiōji, Tokyo, 193-0944, Japan
Novartis Investigative Site
Itabashi Ku, Tokyo, 173 0015, Japan
Novartis Investigative Site
Itabashi Ku, Tokyo, 173 8606, Japan
Novartis Investigative Site
Komae, Tokyo, 201-8601, Japan
Novartis Investigative Site
Koto Ku, Tokyo, 135 8550, Japan
Novartis Investigative Site
Meguro City, Tokyo, 153-8581, Japan
Novartis Investigative Site
Meguro-ku, Tokyo, 152-8902, Japan
Novartis Investigative Site
Minato Ku, Tokyo, 105-8470, Japan
Novartis Investigative Site
Minato-ku, Tokyo, 105-8471, Japan
Novartis Investigative Site
Minato-ku, Tokyo, 108-8639, Japan
Novartis Investigative Site
Mitaka, Tokyo, 181-8611, Japan
Novartis Investigative Site
Musashino, Tokyo, 180-8610, Japan
Novartis Investigative Site
Nerima-ku, Tokyo, 113-0033, Japan
Novartis Investigative Site
Ōme, Tokyo, 198-0042, Japan
Novartis Investigative Site
Shibuya City, Tokyo, 150-8935, Japan
Novartis Investigative Site
Shinagawa Ku, Tokyo, 141 8625, Japan
Novartis Investigative Site
Shinagawa-ku, Tokyo, 142-8666, Japan
Novartis Investigative Site
Shinjuku Ku, Tokyo, 162 8655, Japan
Novartis Investigative Site
Shinjuku Ku, Tokyo, 162 8666, Japan
Novartis Investigative Site
Shinjuku-ku, Tokyo, 160 8582, Japan
Novartis Investigative Site
Shinjuku-ku, Tokyo, 160-0023, Japan
Novartis Investigative Site
Suginami, Tokyo, 166-0001, Japan
Novartis Investigative Site
Sumida-ku, Tokyo, 130-8575, Japan
Novartis Investigative Site
Tachikawa, Tokyo, 190-8531, Japan
Novartis Investigative Site
Yonago, Tottori, 683-8504, Japan
Novartis Investigative Site
Tonami, Toyama, 939-1343, Japan
Novartis Investigative Site
Toyama, Toyama, 930-0194, Japan
Novartis Investigative Site
Toyama, Toyama, 939-8511, Japan
Novartis Investigative Site
Kinokawa, Wakayama, 649-6414, Japan
Novartis Investigative Site
Sakata, Yamagata, 998-8501, Japan
Novartis Investigative Site
Ube, Yamaguchi, 755-8505, Japan
Novartis Investigative Site
Chūō, Yamanashi, 409-3898, Japan
Novartis Investigative Site
Kofu, Yamanashi, 400-8506, Japan
Novartis Investigative Site
Akita, 010-8543, Japan
Novartis Investigative Site
Aomori, 030 8553, Japan
Novartis Investigative Site
Chiba, 260-0852, Japan
Novartis Investigative Site
Chiba, 260-8717, Japan
Novartis Investigative Site
Chiba, 2608677, Japan
Novartis Investigative Site
Fukui, 910-0026, Japan
Novartis Investigative Site
Fukui, 918-8503, Japan
Novartis Investigative Site
Fukuoka, 812-0033, Japan
Novartis Investigative Site
Fukuoka, 813-8501, Japan
Novartis Investigative Site
Fukuoka, 815-8555, Japan
Novartis Investigative Site
Fukuoka, 819-8585, Japan
Novartis Investigative Site
Fukushima, 960-1101, Japan
Novartis Investigative Site
Gifu, 500-8717, Japan
Novartis Investigative Site
Hiroshima, 730-8619, Japan
Novartis Investigative Site
Hiroshima, 731-0232, Japan
Novartis Investigative Site
Hiroshima, 731-5156, Japan
Novartis Investigative Site
Hiroshima, 734-8551, Japan
Novartis Investigative Site
Kyoto, 603-8151, Japan
Novartis Investigative Site
Kyoto, 605-0981, Japan
Novartis Investigative Site
Kyoto, 606 8507, Japan
Novartis Investigative Site
Kyoto, 606-8273, Japan
Novartis Investigative Site
Kyoto, 615-8256, Japan
Novartis Investigative Site
Miyazaki, 880-0041, Japan
Novartis Investigative Site
Miyazaki, 880-8510, Japan
Novartis Investigative Site
Nagasaki, 850-8555, Japan
Novartis Investigative Site
Nara, 630-8305, Japan
Novartis Investigative Site
Niigata, 951 8520, Japan
Novartis Investigative Site
Okayama, 700-8557, Japan
Novartis Investigative Site
Osaka, 534-0021, Japan
Novartis Investigative Site
Osaka, 536-0001, Japan
Novartis Investigative Site
Osaka, 540-0008, Japan
Novartis Investigative Site
Osaka, 542-0081, Japan
Novartis Investigative Site
Osaka, 543-8922, Japan
Novartis Investigative Site
Osaka, 545-8586, Japan
Novartis Investigative Site
Osaka, 553-0003, Japan
Novartis Investigative Site
Ōita, 870-1133, Japan
Novartis Investigative Site
Saitama, 330 8777, Japan
Novartis Investigative Site
Saitama, 330-0074, Japan
Novartis Investigative Site
Saitama, 336-0911, Japan
Novartis Investigative Site
Tochigi, 329-4407, Japan
Novartis Investigative Site
Tokushima, 770-0812, Japan
Novartis Investigative Site
Toyama, 930-0859, Japan
Novartis Investigative Site
Toyama, 930-8550, Japan
Novartis Investigative Site
Wakayama, 640-8558, Japan
Novartis Investigative Site
Wakayama, 641-8510, Japan
Novartis Investigative Site
Yamagata, 990-2214, Japan
Novartis Investigative Site
Yamagata, 992-8502, Japan
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 13, 2022
First Posted
June 16, 2022
Study Start
July 4, 2022
Primary Completion
February 29, 2024
Study Completion
February 29, 2024
Last Updated
March 27, 2024
Record last verified: 2024-03
Data Sharing
- IPD Sharing
- Will not share